---
title: Challenges in the pharmaceutical industry and healthcare market
videoId: EixhVBV2yzo
---

From: [[acquiredfm]] <br/> 

## Introduction to Industry Complexity
The pharmaceuticals sector is described as "without a doubt the most complex industry" studied <a class="yt-timestamp" data-t="00:03:38">[00:03:38]</a>. This complexity existed even before the establishment of regulatory bodies like the Food and Drug Administration (FDA), significant industry consolidation, and the rise of healthcare oligopolies <a class="yt-timestamp" data-t="00:03:46">[00:03:46]</a>.

## Historical Challenges
### The Severity of Diabetes
Historically, Type 1 diabetes was a "death sentence" for children, with "basically nothing that could be done" <a class="yt-timestamp" data-t="00:07:17">[00:07:17]</a>. The accepted treatment was literally called the "starvation diet," an attempt to prolong life, but without a cure, death was inevitable <a class="yt-timestamp" data-t="00:08:17">[00:08:17]</a>.

### Early Insulin Production and Ethics
The initial discovery of insulin in 1921 <a class="yt-timestamp" data-t="00:05:31">[00:05:31]</a> faced immediate scaling challenges, as there was "not enough to go around" <a class="yt-timestamp" data-t="00:12:15">[00:12:15]</a>. Producing insulin from dog pancreases was not practical or ethical for mass production <a class="yt-timestamp" data-t="00:14:04">[00:14:04]</a>.

A significant cultural hurdle was the "firewall between industry and medical science," where "it was perceived to be unethical to make money on taking your medical breakthroughs and sort of turning them into companies" <a class="yt-timestamp" data-t="00:12:25">[00:12:25]</a>. This led to caution and a potential slowdown in development and distribution to prevent excessive profit-making <a class="yt-timestamp" data-t="00:12:47">[00:12:47]</a>.

Farmers were also hesitant to supply animal pancreases due to the disruption it caused to their processes <a class="yt-timestamp" data-t="00:15:03">[00:15:03]</a>.

### Limitations of Early Insulin Products
Early insulin was "barbaric by modern standards" <a class="yt-timestamp" data-t="00:43:35">[00:43:35]</a>:
*   It didn't last long, requiring frequent injections <a class="yt-timestamp" data-t="00:43:41">[00:43:41]</a>.
*   It contained many impurities, leading to swelling, infections, and allergic reactions <a class="yt-timestamp" data-t="00:43:46">[00:43:46]</a>.
*   It was not shelf-stable in liquid injectable form <a class="yt-timestamp" data-t="00:43:55">[00:43:55]</a>; patients had to dissolve solid tablets themselves <a class="yt-timestamp" data-t="00:44:18">[00:44:18]</a>.
*   Patients had to measure and draw solutions into large glass syringes, making accurate dosing difficult without modern measurement tools <a class="yt-timestamp" data-t="00:44:26">[00:44:26]</a>.

### Supply Constraints and the Rise of Type 2 Diabetes
The production of insulin from animal pancreases was severely "scale constrained" <a class="yt-timestamp" data-t="00:55:56">[00:55:56]</a>. For example, by 1980, it took "1 million animals annually for 30,000 diabetes patients," a number far too small for the global demand <a class="yt-timestamp" data-t="00:26:30">[00:26:30]</a>. This limitation meant that Type 2 diabetes was historically not treated with insulin <a class="yt-timestamp" data-t="01:14:12">[01:14:12]</a> due to insufficient supply <a class="yt-timestamp" data-t="01:14:26">[01:14:26]</a>.

## Modern Pharmaceutical Challenges
### Industry Consolidation and Go-to-Market Hurdles
By the late 1980s and early 1990s, the pharmaceutical industry began to consolidate significantly. This made scale "much more important" for R&D, trials and approval, negotiations, and sales <a class="yt-timestamp" data-t="01:21:44">[01:21:44]</a>. The go-to-market aspect transformed, becoming akin to the enterprise software industry where only a few large companies possessed the infrastructure and channels to operate effectively <a class="yt-timestamp" data-t="01:22:20">[01:22:20]</a>.

### The US Healthcare Market's Complexity
The US healthcare system is "unbelievably fragmented" <a class="yt-timestamp" data-t="02:30:13">[02:30:13]</a> and convoluted:
*   **Middlemen**: A simple drug purchase involves numerous parties: manufacturers, distributors, pharmacies, insurance companies, pharmacy benefits managers (PBMs), and often employers <a class="yt-timestamp" data-t="02:33:50">[02:33:50]</a>. This complexity makes it "really hard to have a functioning market to actually interpret demand signals" <a class="yt-timestamp" data-t="02:24:06">[02:24:06]</a>.
*   **PBMs**: These entities, originally meant to negotiate better prices on behalf of many insurance carriers, have become "gatekeepers" <a class="yt-timestamp" data-t="02:42:02">[02:42:02]</a>. A drug manufacturer needs approval from the three major PBMs, which cover about 80% of the market, to be included on their formularies and ensure reimbursement <a class="yt-timestamp" data-t="02:42:24">[02:42:24]</a>.
*   **Rebates**: Manufacturers pay substantial rebates to PBMs, which can account for up to 75% of a drug's sticker price <a class="yt-timestamp" data-t="02:49:47">[02:49:47]</a>. These rebates often do not reach the end consumer <a class="yt-timestamp" data-t="02:50:50">[02:50:50]</a>, creating a "quagmire of a debate" <a class="yt-timestamp" data-t="02:51:17">[02:51:17]</a>.
*   **Incentive Alignment and Time Horizon**: The average American holds a job for 3.7 years, meaning insurance companies face high churn <a class="yt-timestamp" data-t="02:28:34">[02:28:34]</a>. Their incentive is to cover things that pay back within that timeframe or are in high demand <a class="yt-timestamp" data-t="02:28:50">[02:28:50]</a>. This leads to a mismatch where long-term health benefits, like those from weight loss, are not realized by the current insurer or employer, but rather offloaded onto Medicare or other future payers <a class="yt-timestamp" data-t="02:29:28">[02:29:28]</a>.
*   **Medicare Restrictions**: Medicare Part D, which covers prescription drugs, is "legally prohibited from paying for weight loss" medications <a class="yt-timestamp" data-t="02:30:53">[02:30:53]</a>, a rule some attribute to the stigma around obesity <a class="yt-timestamp" data-t="02:31:12">[02:31:12]</a>.

### Challenges with Weight Loss Drugs
*   **Stigma and History**: There is a "huge huge stigma" around weight loss drugs <a class="yt-timestamp" data-t="02:00:32">[02:00:32]</a>, rooted in a history of "dangerous" and "ineffective" medications, such as Fen-Phen, which caused major heart damage <a class="yt-timestamp" data-t="02:00:48">[02:00:48]</a>. Obesity is often viewed as a "personal responsibility problem" despite scientific evidence to the contrary <a class="yt-timestamp" data-t="02:00:56">[02:00:56]</a>.
*   **Industry Avoidance**: Most pharmaceutical companies "completely steered clear" of weight loss research and development due to its problematic history <a class="yt-timestamp" data-t="02:02:53">[02:02:53]</a>.
*   **Efficacy Threshold**: Historically, effective weight loss drugs were deemed impossible to create if they were also safe <a class="yt-timestamp" data-t="02:01:28">[02:01:28]</a>. There's a "magic number" of safely enabling someone to lose 10% of their body weight or more for a viable market to exist <a class="yt-timestamp" data-t="02:03:44">[02:03:44]</a>.

### R&D and Financial Risks
*   **High Costs**: Bringing a drug to market is "incredibly Capital intensive," averaging $2.3 billion per drug today, compared to $40 million (inflation-adjusted) in 1953 <a class="yt-timestamp" data-t="02:48:45">[02:48:45]</a>.
*   **Low Success Rate**: Pharmaceutical development is a "super high risk," "super high return" venture <a class="yt-timestamp" data-t="03:11:46">[03:11:46]</a>. From 100 drugs entering clinical development, only 10 make it to market, and *one* provides half of the industry's profits <a class="yt-timestamp" data-t="03:12:31">[03:12:31]</a>. Most approved drugs do not even earn back their R&D costs <a class="yt-timestamp" data-t="03:13:02">[03:13:02]</a>.
*   **Long Time Horizons**: Research and development can take over a decade before any fruit is borne <a class="yt-timestamp" data-t="03:12:01">[03:12:01]</a>.
*   **"Better Than The Beatles" Problem**: FDA approval requires a drug to be statistically "better than current alternatives" <a class="yt-timestamp" data-t="03:10:02">[03:10:02]</a>, making it harder to get approval for conditions with existing treatments <a class="yt-timestamp" data-t="03:10:07">[03:10:07]</a>. This pushes companies towards developing drugs for rare diseases or those without current solutions <a class="yt-timestamp" data-t="03:11:15">[03:11:15]</a>.

## Current Industry Issues
### Insulin Market Disruption
The attractiveness of operating an insulin business has "completely fallen apart" recently <a class="yt-timestamp" data-t="02:40:37">[02:40:37]</a> due to:
*   **Pricing Controversy**: US officials alleged price increases of over 600% between 2001 and 2019 <a class="yt-timestamp" data-t="02:41:37">[02:41:37]</a>.
*   **Regulation**: Price caps were introduced following public outcry <a class="yt-timestamp" data-t="02:42:17">[02:42:17]</a>.
*   **Biosimilars**: The introduction of biosimilar insulin "completely arbitraged away" profits <a class="yt-timestamp" data-t="02:42:38">[02:42:38]</a>.
*   **GLP-1 Impact**: New GLP-1 drugs have also reduced demand for insulin <a class="yt-timestamp" data-t="02:42:44">[02:42:44]</a>.

### GLP-1 Specific Challenges
*   **High Sticker Price**: In the US, GLP-1 drugs like Ozempic cost over $1,000 per month, and Wegovy over $1,300 per month, before insurance <a class="yt-timestamp" data-t="02:27:30">[02:27:30]</a>.
*   **Supply Constraints**: Despite massive demand, companies like Novo Nordisk face "years worth of Supply constraint demand pipeline" <a class="yt-timestamp" data-t="02:20:00">[02:20:00]</a>.
*   **Side Effects**: Common side effects include nausea, vomiting, and constipation, severe enough for about "one out of six patients" to discontinue the drug <a class="yt-timestamp" data-t="02:17:41">[02:17:41]</a>.
*   **Non-adherence**: As many as 68% of people stop GLP-1 treatment after a year <a class="yt-timestamp" data-t="02:39:10">[02:39:10]</a> due to price, insurance changes, supply issues, or side effects <a class="yt-timestamp" data-t="02:39:17">[02:39:17]</a>.
*   **Lean Muscle Mass Loss**: Early studies suggest a disproportionate loss of lean muscle mass on GLP-1s compared to traditional diet and exercise <a class="yt-timestamp" data-t="03:35:50">[03:35:50]</a>.
*   **Payer Concerns**: Payers (insurance companies, employers, Medicare) are "scared" of the short-term costs if they start covering these drugs broadly, given that 40% of the US population is obese <a class="yt-timestamp" data-t="02:34:06">[02:34:06]</a>.

### Broader Healthcare System Issues
*   **Declining Returns on Investment**: For every dollar invested in the healthcare system, there's a perceived "less and less incremental utility" <a class="yt-timestamp" data-t="03:14:00">[03:14:00]</a>. Healthcare costs as a percentage of GDP have surged from 5% in 1960 to 17-18% today <a class="yt-timestamp" data-t="03:14:34">[03:14:34]</a>.
*   **Decreasing Life Expectancy**: Despite increased spending, average life expectancies in America have declined in recent years, often due to mental health-related issues, drug overdoses, and other factors outside the direct control of the healthcare system <a class="yt-timestamp" data-t="03:16:26">[03:16:26]</a>.
*   **System Design**: The current healthcare system was designed to treat "acute and infectious diseases" <a class="yt-timestamp" data-t="03:19:00">[03:19:00]</a>. The "next frontier" is chronic illnesses, which require a "very different way of thinking of regulating, of paying for" <a class="yt-timestamp" data-t="03:19:42">[03:19:42]</a>.
*   **Health Insurance as "Access"**: US health insurance is not truly insurance in the sense of risk-sharing for major losses, but rather "access" to services <a class="yt-timestamp" data-t="03:29:57">[03:29:57]</a>. During crises like COVID, the profits of large health insurers remained flat or grew, implying that taxpayers ultimately fund major calamities, not the insurers <a class="yt-timestamp" data-t="03:30:02">[03:30:02]</a>.
*   **Oligopoly and Lack of Innovation**: The healthcare system suffers from "oligopoly," "regulatory capture," and "too many middlemen" <a class="yt-timestamp" data-t="03:15:19">[03:15:19]</a>. While pharmaceutical companies take significant innovation risks, other parts of the ecosystem (insurers, PBMs) are highly consolidated and insulated, not showing similar innovation or risk-taking <a class="yt-timestamp" data-t="03:30:38">[03:30:38]</a>.

### The Profit Dilemma
Despite high gross margins on successful drugs (e.g., Novo Nordisk at 84% <a class="yt-timestamp" data-t="02:28:28">[02:28:28]</a>), the pharmaceutical industry's overall return on invested capital (ROIC) is often "not through the roof" <a class="yt-timestamp" data-t="03:24:43">[03:24:43]</a>, aligning with other industries like Trucking or broadcasting <a class="yt-timestamp" data-t="03:24:51">[03:24:51]</a>. This is because profits from winners must subsidize all the failures and significant R&D costs <a class="yt-timestamp" data-t="03:24:30">[03:24:30]</a>.